We observed that anti-PD1 therapy effectively reduced the expression of PD-1 on CD4+ and CD8+ lymphocytes in the glioma TME (Fig. 4E), but no additional effects of combined siGal-1 treatment. The gene discussed is PDCD1; the disease is central nervous system cancer.